

aaaai.org

AAAAI's quarterly digital membership magazine

ELSEVIER

JAC The Journal of Allergy and Clinical Immunology: GLOBAL

An Official Journal of the

AAAAI Introduces New Journal

Learn more about JACI: Global and how to submit your research on page 10.

American Academy of Allergy Asthma & Immunology VIRTUAL ANNUAL MEETING FEBRUARY 26-MARCH 1, 2021

Review session recordings and claim continuing education credits through March 1, 2022.

> Incorporating New and Emerging Therapies Into Allergy/Immunology Practice and Research

> > annualmeeting.aaaai.org

#AAAAI21



aaaai.org

Board of Directors President

Giselle S. Mosnaim, MD, MS, FAAAAI

President-Elect David A. Khan, MD, FAAAAI

Secretary-Treasurer Jonathan A. Bernstein, MD, FAAAAI

Immediate Past President Mary Beth Fasano, MD, MSPH, FAAAAI

At-Large Members

Stuart L. Abramson, MD, PhD, AE-C, FAAAAI Leonard B. Bacharier, MD, FAAAAI Paula J. Busse, MD, FAAAAI Timothy J. Craig, DO, FAAAAI Carla M. Davis, MD, FAAAAI Denise A. DiPrimio-Kalman, DO, FAAAAI Tamara T. Perry, MD, FAAAAI Wanda Phipatanakul, MD, FAAAAI Thanai Pongdee, MD, FAAAAI Sarbjit (Romi) Saini, MD, FAAAAI Frank S. Virant, MD, FAAAAI Paul V. Williams, MD, FAAAAI

IMPACT Editorial Team

Executive Vice President Thomas A. Fleisher, MD, FAAAAI

Executive Director Rebecca Brandt, CAE

Publication Manager April Presnell

For address changes, contact the AAAAI, 555 E. Wells Street, Suite 1100, Milwaukee, WI 53202-3823 telephone (414) 272-6071 fax (414) 272-6070 email info@aaaai.org

Copyright ©2021 by the American Academy of Allergy, Asthma & Immunology.

The American Academy of Allergy, Asthma & Immunology does not endorse products or services from related industries, associations or organizations and reserves the right to change any copy that may be inconsistent with this policy. As such, any external advertisements that appear in IMPACT are not an endorsement of their products or services.

IMPACT (ISSN 1094-4745) is published quarterly by the American Academy of Allergy, Asthma & Immunology (AAAAI). It reports news as it affects the specialty, practices, patients, and the profession; and provides information on AAAAI programs and activities.



1()

8



- 4 President's Message
- 5 What's New at aaaai.org Featured CME Opportunities
- 6-7 Meet Some of the Young Investigators Who Are Rising Stars Within the Specialty

Immunol

ELSEVIER

Contents

- 8-9 How the Chrysalis Project Helps Future A/I Healthcare Professionals
- 10 AAAAI Introduces New Journal
- 11 AAAAI Updates Its Online Disclosure System
- 12-13 Member Spotlight
- **14-15** Is Your Practice Ready for Future Pandemics or Other Emergencies?
- 16-17 The AAAAI Annual Meeting Returns as a Hybrid Event in 2022
 - **18** How You Can Provide the Right Medical Support for Primary Immunodeficiency Patients
 - 19 The State of Pollen Data Collection and Research
 - 20 In Brief
 - 21 June 2021 Board of Directors Meeting Summary
- 22-23 AAAAI Welcomes Incoming Fellows and Members

President's Message

Giselle S. Mosnaim, MD, MS, FAAAAI 2021–2022 AAAAI President



Dear Colleagues,

Within my message in the spring issue of *Impact*, I had expressed growing optimism regarding the ongoing COVID-19 pandemic. Unfortunately, that has since been tempered due to the spread of the highly contagious Delta variant, which has quickly become the dominant strain here in the United States.

Based on what we know thus far about the Delta variant, it's clear that getting vaccinated against COVID-19 has never been more important.

Although vaccination rates are rising again due to the surge in COVID-19 cases caused by the Delta variant, many still remain vaccine hesitant. In a recent message from the AAAAI COVID-19 Response Task Force, the resources <u>here</u> and <u>here</u> were shared to allow you to better understand what these individuals may be thinking and provide language to help improve vaccine acceptance. Other resources to use with your patients to help improve vaccine acceptance include:

- A dedicated section on <u>Talking to Your Patients About the CO-</u> <u>VID-19 Vaccine</u> available from the <u>AAAAI COVID-19 resources page</u>
- A new AAAAI infographic in <u>English</u> and <u>Spanish</u> that conveys the importance of getting vaccinated
- Episode 45 of our Conversations from the World of Allergy podcast series that features Juanita Mora, MD. She discusses the origins of vaccine hesitancy among patients from various backgrounds, and offers practical tips for addressing these complex issues with individual patients and on a broader scale.

Another new podcast episode that was recently released focuses on a National Institutes of Health (NIH) trial where researchers are seeking individuals who experienced a severe allergic reaction to the first dose of the Pfizer-BioNTech or Moderna COVID-19 vaccine. Participants will receive the second dose in a safe environment at the NIH Clinical Center in Bethesda, Maryland, while allowing researchers to assess the safety and possible causes of allergic reactions. This study will provide crucial information to allergists and providers to guide their patients regarding allergic reactions to the mRNA vaccines, and will address general public anxiety related to these reactions.

Pamela Guerrerio, MD, PhD, who was the guest for the podcast episode and is principal investigator for the clinical trial and a past recipient of the AAAAI Foundation Faculty Development Award, said: "We hope to determine whether people who had a systemic allergic reaction to the first dose of the mRNA COVID-19 vaccines can safely receive a second dose, which may be necessary to achieve full protection against COVID-19. We hope this study will also provide insight into the mechanisms underlying these reactions."

If you have patients who are interested in participating, please tell them to visit the <u>ClinicalTrials.gov page</u> for important details. They can also email <u>prpl@cc.nih.gov</u> or call (800) 411-1222 and refer to study #000460-I.

Learn the Latest Updates on the AAAAI's New Third Journal

As previously announced, the AAAAI is expanding its journal portfolio to include a Gold Open Access journal, and David B. Peden, MD, MS, FAAAAI, will serve a five-year term as the first Editor-in-Chief of this new journal named *The Journal of Allergy and Clinical Immunology: Global* (JACI: *Global*).

JACI: *Global* will provide authors who are mandated to publish in a fully open access journal or whose work is not suitable for our existing AAAAI journals, the opportunity to publish in a journal that will reach not only the AAAAI community, but the global community, with no barrier to access for anyone with an internet connection.

Now you can turn to page 13 to read some exclusive updates on JACI: *Global*, which will soon begin accepting manuscript submissions in order to meet our ambitious timeline of publishing the first issue online in February 2022.

What the AAAAI's Chrysalis Project and the AAAAI Foundation's Faculty Development Awards Have in Common

While you can read about the Chrysalis Project on page 8 and 2021 AAAAI Foundation Faculty Development Award recipients on page 6, what these two highly successful initiatives have in common is that they are a pipeline for those who go on to make significant contributions to the field of allergy and immunology. I mentioned earlier in this message the important NIH study that will provide crucial information to allergists and providers to guide their patients regarding allergic reactions to the mRNA COVID-19 vaccines—and how Pamela Guerrerio, MD, PhD, a past recipient of the AAAAI Foundation Faculty Development Award, is serving as principal investigator for this clinical trial. On page 8, you will read some examples of past Chrysalis Project participants who have also gone on to make significant contributions to our specialty, including Adora A. Lin, MD, PhD, FAAAAI, who went on to become a recipient of the AAAAI Foundation Faculty Development Award herself.

The Chrysalis Project and the AAAAI Foundation Faculty Development Award are truly investments in the future of our specialty, and the return on investment is tremendous. To further illustrate this, the Foundation did a grant impact study last year and found that 94% of our award recipients have achieved permanent A/I faculty positions, approximately \$7.12 million has been granted as major awards since 1993, and nearly \$82.4 million more has been granted to our award recipients after the Foundation provided initial support. Please keep these astonishing figures in mind as you read the interviews with our latest Faculty Development Award recipients on page 6.

I am eager to see what our Faculty Development Award recipients and our Chrysalis Project participants continue to do to impact the future of allergy and immunology. And if you are a past Faculty Development Award recipient or Chrysalis Project participant yourself, please know the AAAAI is so proud of you.

Sincerely,

Huille Mesnain MO/NS FAAAAI

Giselle S. Mosnaim, MD, MS, FAAAAI AAAAI President president@aaaai.org

American Academy of Allergy, Asthma & Immunology

An allergist / immunologist membership organization dedicated to advancing the knowledge and practice of allergy, asthma and immunology for optimal patient care



What's New at aaaai.org

New Eosinophilic Esophagitis (EoE) Quiz for Your Patients

EoE is one of the most searched related conditions on aaaai.org. Find out how much your patients know about EoE by letting them take our new quiz in the Conditions & Treatments section of the website. The quiz will teach them about triggers, medications and more. The quiz in available in English and Spanish.

Read the Expanded Systemic Mastocytosis Overview

Systemic mastocytosis can be complicated for patients to understand. Our newly updated information expands on the symptoms, diagnosis, treatment and management of this condition. Your patients can find the article in the Conditions & Treatments section of the website in <u>English</u> and <u>Spanish</u>.

Methods of Aeroallergen Immunotherapy: Proven, Unproven, and Everything in Between

Allergen immunotherapy is a treatment for allergies that has been around for over a century. There are thousands of studies showing its effectiveness, but patients might not understand the differences. A new article talks about subcuteanous immunotherapy (SCIT), sublingual immunotherapy (SLIT) and intralymphatic immunotherapy (ILIT). This article can be found in English and Spanish in the Conditions Library under the Tools for the Public section of the website.

Featured CME Opportunities

Save the Date for the Next Virtual Journal Club Webinar Presented by JACI: *In Practice* and NAIA

The next Virtual Journal Club webinar, which is a free event allowing you to discuss recently published research that is relevant to clinical practice, is coming up on September 8. Previous webinars have been recorded and are available for viewing and credit claiming <u>here</u>.

Understanding Hypereosinophilic Syndrome (HES) and Its Treatment

The AAAAI has partnered with Medscape on this new online module, which will teach you about the pathophysiology and treatment of HES. <u>You can find the course on the Medscape website</u>.

Demystifying IgE-Mediated Cow's Milk Allergy: Diagnosis and Management: 2021 Update

Diagnosis and management of cow's milk allergy can be challenging and impact quality of life. This <u>online module</u> is designed to help you diagnose and manage cow's milk allergy in your practice.

Oral Immunotherapy (OIT) for Treatment of Food Allergy: 2021 Update

<u>This interactive course</u> provides information about the different types of food immunotherapy. Examine the current evidence supporting OIT's use, and the importance of shared decision making with patients and families to identify which patients might benefit most from this therapy.

Providing Enhanced Medical Support for Patients with Primary Immunodeficiency Disorders (PIDD): A Patient-Guided Intervention to Ensure Patient Engagement During a Global Pandemic and Beyond This new course series will help you provide the correct medical care and support to your PIDD patients. Learn more about this new course on page 18, or <u>click here</u>.

Meet Some of the Young Investigators Who Are **Rising Stars** Within the Specialty

Learn More About the 2021 AAAAI Faculty Development Award Recipients

You've made it possible for the AAAAI Foundation to be able to grant four Faculty Development Awards in 2021. These mentored awards give researchers essential, protected time at the bench so they can dig deeper into their research to advance our understanding of allergic disease—leading to healthier and happier patients.

We're excited to give you the chance to learn more about these young investigators and the research they're working on.



Derek Chu, MD, PhD



Title: "Tree Nut Allergen Thresholds, Biomarkers, and Methods of Desensitization - TITAN and TRADE Studies"

Q: How has the Faculty Development Award impacted you personally and professionally?

A: The AAAAI Foundation Faculty Development Award provides critical support for two critical studies to address

gaps in understanding and treating food allergy. I am passionate about the field of allergy/immunology, both in terms of clinical care and biomedical research. Through this AAAAI Faculty Development Award, I will further my clinician-scientist progression towards my long-term goal of contributing to medicine, science and society. The support of the award will be essential towards materializing that vision into reality.

Torie Grant, MD



Title: "Allergen Exposure Reduction as a Disease-Modifying Strategy in Allergen-Sensitized Children with Asthma" **Q: What and/or who encouraged you**

to pursue a career in A/I and academic research?

A: I have been in Baltimore, Maryland for all of my medical training, where as an early medical student I noticed the high volume

of children and adults with severe asthma in the emergency room and hospital wards. During an elective in allergy and immunology, I was drawn to caring for patients from childhood into adulthood. This attraction led to my pursuit of a combined residency in internal medicine and pediatrics. Both residency disciplines were filled with patients suffering frequent asthma exacerbations and associated hospitalizations. I continued to find myself compelled by the urban asthma population and what unique risk factors could be contributing to their asthma. As my interest grew, I recognized that formal advanced training in allergy and immunology was necessary in order to adequately address this question.

Melanie Ruffner, MD, PhD



Title: "Investigation of the Role of STAT6 Signaling in Proton-Pump Inhibitor Response in Eosinophilic Esophagitis"

Q: Can you tell us more about your research, your findings and how they will impact the A/I field, clinical practices and patients? What clinical application do you foresee from this research? A: Proton pump inhibitors are one of

the first-line medications that can be used to treat patients with eosinophilic esophagitis (EoE). However, it is not known how these medications reduce inflammation in the esophagus of patients with EoE. We are studying how proton pump inhibitors affect the function of esophageal epithelial cells to better understand how these medications help patients with EoE.

Cosby Stone, MD, MPH



Title: "Defining the Key Epidemiologic and Immunogenetic Risk Features of True IgE Mediated Cephalosporin Allergy"

Q: What are your future research and career goals?

A: I started with a focus on penicillin allergy, and have subsequently branched out in my thinking to include cephalosporin antibiotic allergy (the focus of my AAAAI Faculty

Development Award). These antibiotics are crucial to a large number of patients and are the first line for almost anything in the hospital. I will study whether there are patients whose reported cephalosporin allergies are low risk enough for direct challenge without preceding skin testing, how long their cephalosporin allergies last, and whether there are immunogenetic risk factors that make them more likely to get those allergies.

In the long run, I see this model of research (who's at risk of being truly allergic, why did they get that allergy?) as being something that needs to be done for almost every drug allergy. It gives people more options at the point of care, and will hopefully allow for optimized use of resources and improved antimicrobial stewardship. There is lots of excitement for me knowing that I'll never run out of work to do. New drugs are invented every year.

You can read the full interviews with the awardees on the <u>AAAAI</u> Foundation website.

AAAAI FOUNDATION 🔒 📝 🔊 🖆 🖋 FACULTY DEVELOPMENT AWARD

2022 Faculty Development Award Letters of Intent Due September 7

The AAAAI Foundation is accepting Letters of Intent through September 7 for the 2022 Faculty Development Award. Each Faculty Development Award provides at least \$240,000 in funding over a three-year period. These mentored awards are given to further the development of junior faculty into independent investigators by funding excellent research that will strengthen the A/I specialty.

The AAAAI Foundation is committed to increasing ethnic and racial diversity in the A/I field, and strongly encourages minority applicants to apply. Further, the AAAAI Foundation is committed to geographic diversity in the A/I field, and strongly encourages applications from diverse geographic areas, especially those where few AAAAI Foundation grants have been awarded.

For further details, please visit <u>aaaaifoundation.org/research</u>.

How the Chrysalis Project Helps Future A/I Healthcare Professionals



Asriani M. Chiu, MD, FAAAAI



Rebecca Saff, MD, PhD, FAAAAI

The AAAAI Chrysalis Project presents a great opportunity for U.S. and Canadian medical students and residents to explore a career in allergy/immunology. For over a decade, this project has mentored talented students and helped them follow the path of A/I towards a rewarding career, whether that is in practice or academia.

This year, the Chrysalis Project has two new co-chairs, Asriani M. Chiu, MD, FAAAAI, of the Medical College of Wisconsin, and Rebecca Saff, MD, PhD, FAAAAI, of Massachusetts General Hospital. Dr. Chiu works as a Professor of Allergy and Immunology and is the Program Director of Allergy and Immunology Fellowship Training at her institution. Dr. Saff works as the A/I Fellowship Director and teaches at

Harvard Medical School, while also practicing at Massachusetts General Hospital.

We asked Dr. Chiu to tell us more about the Chrysalis Project and her role as co-chair. "I am so excited to be a new co-chair for the Chrysalis Project! The Chrysalis Project has always been an outstanding program, and helps interested medical students and residents get a more in-depth look at our A/I specialty during the AAAAI Annual Meeting. The selected participants are paired with fellow-in-training (FIT) mentors, they have their own didactic program of lectures by experts in a variety of A/I topics, and there is also a panel discussion that includes the many different careers and opportunities for the allergist/immunologist: academics, industry, private practice, and research."

"There are also a few networking events to help the participants get to know allergist/immunologists from around the country and even locally within their own programs, which build solid relationships for the future. This past year was a virtual program, which was excellent, but next year we are looking forward to meeting in person in Phoenix. We are also very excited to be able to offer more opportunities for more diverse participants this upcoming year. I remember when the Chrysalis Project first started, and personally know several past participants (when they were still in training and I recommended that they participate in this program) who are now colleagues and friends. It will be hard to 'replace' Kimberly A. Risma, MD, PhD, FAAAAI, and her outstanding leadership, but I look forward to working with Dr. Rebecca Saff as co-chair, and the other members and staff of the Chrysalis Project."



Dr. Saff also offered her insights about the project. "I participated in the Chrysalis Project as a resident, and it helped confirm my decision to apply for an allergy/immunology fellowship. I became involved with Chrysalis as part of my AAAAI Leadership Institute project, when I organized discussions on hot topics in A/I for the 2018 Chrysalis Project program. It's an incredible program that gives interested medical students and residents a chance to experience how fascinating our field is and to meet mentors who can answer their questions and encourage their interest. We are excited to be back in person next year and hope we can bring a group of diverse medical students and residents to Phoenix, and share our enthusiasm for allergy/immunology with them."

Many previous Chrysalis Project participants have gone on to make significant contributions to the field of A/I.

Past participant Christina G. Kwong, MD, is now New Allergist/Immunologist Assembly (NAIA) Vice-Chair after previously serving as FIT Committee Chair. "Being a part of the Chrysalis Project was a major factor in solidifying my commitment to becoming an allergist/ immunologist," she said. "I was able to see a big picture overview of the specialty and that the AAAAI clearly plays a key role in education, collaboration and exploring frontiers."

Another past participant, Adora A. Lin, MD, PhD, FAAAAI, went on to become a recipient of the 2018 AAAAI Foundation Faculty Development Award for her project "Elucidation of the Role of B Cells in Food Allergy, Sensitization, and Tolerance." When asked about the Chrysalis Project, she said, "Before

participating, I knew that I was interested in a specialty that cared for patients with immune-mediated diseases. After the Chrysalis Project, I began to think seriously about specializing in allergy/ immunology and sought clinical rotations in allergy/immunology



Christina G. Kwong, MD



Adora A. Lin, MD, PhD, FAAAAI



clinics, which solidified my decision. The Chrysalis Project really showed me the breadth of conditions one sees as an allergist/ immunologist, and being at the AAAAI Annual Meeting allowed me to see the exciting research happening in the field. I also was exposed to a group of physicians, from trainees to leaders, who were excited about their specialty and were invested in securing its future. I recommend participating in the Chrysalis Project to any medical student and resident who is interested in A/I."

The core of the Chrysalis Project is a program that takes place during the AAAAI Annual Meeting. The 2022 program will take place in Phoenix from February 24-26. Sixty participants will be selected and invited to participate in all Chrysalis Project educational programming and events. This includes the participant welcome/ registration, the didactic program, FIT mentor luncheon, career paths in A/I session and the Chrysalis Project reception. Participants are also invited to attend the President/President-Elect Reception and will be paired with a FIT and faculty mentor. Best of all, Annual Meeting registration for those accepted is completely free.

The application for the 2022 Chrysalis Project is open now and will close on October 25 at 11:59 am CT.

If you are interested, or know someone else who might be, direct them to the program page here.

2022 Chrysalis Project Program Schedule Phoenix, Arizona

Thursday, February 24, 2022

Chrysalis Project Participant Welcome and Registration: 6:00 to 7:00 pm MT

Friday, February 25, 2022

Chrysalis Project Didactic Program: 7:30 am to 12:35 pm MT

Luncheon with FIT Mentors and Didactic Program Faculty: 12:35 to 1:15 pm MT

AAAAI President/President-Elect Reception: 7:00 to 9:00 pm MT

Saturday, February 26, 2022

Career Paths in Allergy and Immunology Session: 12:00 to 1:45 pm MT

Chrysalis Project Reception with FIT Mentors and Faculty: 6:00 to 7:00 pm MT



Meet Dr. David B. Peden, JACI: Global Editor-In-Chief



Dr. David B. Peden is the Harry S. Andrews Professor of Pediatrics, Medicine and Microbiology/ Immunology and serves as the Senior Associate Dean for Translational Research and Medical Director, Center for Environmental Medicine, Asthma & Lung Biology for the University of North Carolina School of Medicine. He is currently principal investigator for over \$5 million of federally grant funded research from the Department of Defense, Environmental Protection Agency, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, and National Institute of Environmental Health Sciences. His research program focuses on assessing human inflammatory response to ozone, endotoxin, concentrated air particulates and woodsmoke particles, identifying biological determinants of response, and testing interventions to mitigate these effects and for

treatment of airway disease. Dr. Peden is also a past President of the AAAAI and Chair of the FDA Allergenic Products Advisory Committee. He is certified in pediatrics, allergy and immunology, and clinical laboratory immunology.

Manuscript Submissions Open September 1, 2021

JACI: *Global* will accept manuscripts beginning September 1, 2021. Submissions can be made through the journal's Editorial Manager submission portal: <u>https://www.editorialmanager.com/jacig/default.aspx</u>.



JACI: *Global* will provide authors a high-quality outlet for authors whose funders require them to publish open access as a condition of their funding. It also provides researchers whose work is sound science, but does not meet the criteria of the other AAAAI journals, the opportunity to publish in a journal that will reach a global audience.

JACI: *Global* will be particularly appealing to authors working in Research4Life countries, with waivers or deep discounts of accepted Article Processing Charges (APCs) automatically provided by the journal's publisher, Elsevier. It will

also provide an important service to the growing number of funders who have joined Plan S (the European cOAlition S initiative that requires full open access of research funded by its 25 members, starting in 2021), including the Gates Foundation, the Wellcome Trust, UK Research and Innovation, and the World Health Organization.

AAAAI Introduces New Journal

When the first issue of the AAAAI's new Gold Open Access journal—*The Journal of Allergy and Clinical Immunology: Global* (JACI: *Global*)—launches early next year, it will provide authors the opportunity to publish in a journal that will reach the global community, with no barrier to access for anyone with an internet connection.

JACI: Global's first official issue will be

AAAAI Annual Meeting in Phoenix,

with manuscript submissions being

JACI: Global will publish reports of

and clinical-related to all aspects

of allergy, immunology, and related fields. It joins the AAAAI's distinguished

family of journals: JACI, the most

cited journal in the field of allergy

and clinical immunology, and JACI: In

Practice, which places an emphasis on

practical clinical research and the latest

"One of JACI: Global's hallmarks will be geographic diversity

of JACI: Global. "We hope to provide a venue for international

authors committed to A/I who provide important insights

with an emphasis on global and regional research and practice," said David B. Peden, MD, MS, FAAAAI, Editor-in-Chief

recommendations for diagnosis and

treatment.

accepted starting September 1, 2021.

original research—basic, translational

published in February 2022 during the

into regional A/I standards of care. We will also be a platform for reports on basic science and early stage clinical and population studies relevant to the specialty".

As the Gold Open Access companion journal to AAAAI's two leading hybrid subscription journals, JACI and JACI: *In Practice*,



AAAAI Updates Its Online Disclosure System

Review the New Standards and Improved Online Disclosure System

AAAAI members provide disclosures of their financial relationships in the Online Disclosure System for many reasons, such as authoring work group reports, serving on committees, and teaching as faculty at the AAAAI Annual Meeting or for other CME offerings. The next time you are asked to update your disclosure, you will see some changes and improvements to the system.

In late 2020, the Accreditation Council for Continuing Medical Education (ACCME) updated their standards related to financial disclosures for CME activities. The AAAAI's Ethics/Conflict of Interest Committee updated the AAAAI's Disclosure Policy to align with these changes. The new Online Disclosure System will allow the AAAAI to stay in compliance with these new standards, while improving the experience for members who are providing a disclosure.

The major changes you will see in the Online Disclosure System include:

• You are now required to disclose all financial relationships from the previous 24 months. In the past, only 12 months' worth of history needed to be disclosed.

- • You will only need to disclose your financial relationships. You no longer need to disclose those of your spouse or immediate family members.
- If you report research funding, you will now report the full amount of each grant. In the past, only the portion of the grant supporting your salary was required.
- The definition of organizations considered to be industry and that present a conflict of interest has been revised. Please review this information in the AAAAI's Disclosure Policy and on the form to familiarize yourself with this change.

You will also see some improvements to the Online Disclosure System. These include:

- • A simplified disclosure form All financial relationships will be disclosed in the same format.
- • **Mobile compatibility** You can now complete the form on a smartphone or other portable device.

To review the updated Disclosure Policy and Online Disclosure System, visit <u>aaaai.org/disclosure</u>. If you have questions, please contact <u>cme@aaaai.org</u>.

Member Spotlight

Region 5 Mid South RSL Governor Louise H. Bethea, MD, FAAAAI

What are you doing to support the field of A/I?

The practice of allergy, asthma and immunology has had encroachment by physicians in many different specialties and by physician extenders. This is happening in every state including Texas where I live and practice allergy. I represent allergists in Texas at the county and state level with the Harris County Medical Society and the Texas Medical Association (TMA), playing a visible role in promoting allergy-related legislation, working with TMA lobbyists, serving on committees discussing insurance and practice issues affecting our specialty and other specialties, and giving our specialty visibility before other physicians. I have worked with my congressman to change and promote legislation to improve patient care, and we also addressed Medicaid and Medicare issues. Improving and promoting legislation relevant to the practice of allergy is an essential goal. Representing our society, I have testified before the Texas legislature. This work has significantly improved legislation encouraging medical care for patients with allergy and other related problems.

What are some of the biggest challenges you are trying to address in the Mid South RSL region when it comes to A/I?

The Mid South region has the same issues as those in other areas: insurance reimbursement, Medicare and Medicaid issues, prior authorizations and telemedicine. We all have suffered mentally, physically and financially because of the COVID-19 pandemic. As Region 5 Governor, I am trying to encourage active participation from the state society presidents in organized medicine and the AAAAI in particular. Their input in our society is essential. All of us have busy practices, family responsibilities and only limited time. Coordinating these with active participation is a challenge, but to be a strong society we need allergists' participation and input. Active participation in the society will result in a significant improvement in patient care and the practice of medicine. How has COVID-19 impacted your work as a physician? What about your role as an RSL Governor? COVID-19 has made me

evaluate improvements and look at other ways to practice medicine including telemedicine.

Although in Texas physicians were considered essential for most of the pandemic, in other states practices were closed. We were not able to perform as many procedures either. The challenge has been managing our patients with the limitations imposed and treating patients with COVID-19 and other illnesses through telemedicine, thus providing needed care. Our role in treating immunodeficiency patients has been critical. We now feel responsible for assuring our patients of the importance of COVID-19 vaccinations, providing evidence-based answers and explaining and evaluating reactions, and dispelling falsehoods about the vaccines. Many of us have been able to continue our relationships with our colleagues through Zoom meetings, supporting each other to prevent burnout, continuing to keep abreast of everchanging information on COVID-19, and using our knowledge with patients and colleagues to support science in the practice of medicine all with the help of the AAAAI.

What inspired you to get involved with the AAAAI's RSL Assembly?

The RSL Assembly is a wonderful way to promote communication between the AAAAI and our state societies. The AAAAI is very active in its mission to support the practicing allergist. They have kept us abreast of information on COVID-19. I welcomed the opportunity given to me to work with our RSL Assembly to support the practicing allergists who each day deal with various issues and concerns as they care for patients. These allergists are willing to share their concerns with the AAAAI so it can evaluate and work on solutions. We are there to support and assist community practicing allergists and academic allergists as they provide high quality, appropriate care for their patients.



What's one thing—either related to A/I or not—you learned in the last month?

The July issue of Scientific American has an interesting article discussing artificial intelligence and the creation of artificial proteins. This article goes on to discuss how AI by Google's DeepMind can calculate how the atoms in a unique array of amino acids are going to arrange themselves, allowing sculpting of proteins. By using synthetic proteins developed in labs of the University of Washington, these proteins can then be designed using amino acid by amino acid to fit precisely against a virus's receptor binding domain (RBD). These labs have developed a prototype—a nano particle sphere displaying 60 copies of the RBD—and tethered the RBDs to short strings of these amino acids, allowing the immune system to produce more antibodies than our current systems of immunizations. This would allow us to deliver more immunizations through "a spritz in the nose rather than by injection." These artificial proteins with the help of AI could vastly improve our treatment of infectious diseases and revolutionize the field of immunology and vaccinology.

What is the Federation of Regional, State & Local Allergy, Asthma & Immunology Societies (RSLAAIS) Assembly?

The AAAAI's RSLAAIS Assembly (also known as the RSL Assembly for short) consists of more than 70 regional, state and local societies (RSLs) who promote, support and advocate for allergist/immunologists at a grassroots level. The assembly assists in providing support, tools and effective methods to ensure allergist/immunologists are recognized as the premier providers of quality A/I care.

The assembly is led by a <u>leadership team of nine physicians</u> representing seven distinct geographical regions of the country. This enables the AAAAI to more easily connect with local societies and provides an open line of communication between the organization, local, and state societies. It also allows the AAAAI to learn more about the concerns of our members, from state legislation to training programs, and in recent months, even PPE supply levels. RSL Governors are an integral part of the work done by the AAAAI.



Breathe Easier With Carpet.

CHANGE IS IN THE AIR.

It's official: Scientific research shows the positive impact of carpet on indoor air quality.



uncover more at carpet-rug.org

Is Your Practice Ready for Future Pandemics or Other Emergencies?

While the COVID-19 pandemic is by no means over, it is a reality that most of us have come to live with and adapt to the best we can. But what about future pandemics or other emergencies? If your practice hasn't put new policies in place, it's time to start working on them.





How to Develop Your Emergency Plan

When developing an emergency plan, there are a few things you need to keep in mind.

The first is that during an emergency such as a pandemic, there will likely be a reduced workforce, as we saw during COVID-19. This could be due to employee absenteeism, budget cuts, or safety measures put into place by the government. Consider building in a sick leave policy that will not penalize employees who become ill. You should also identify which positions are essential for the operation of your practice to ensure policies are put into place that allow those individuals to keep everything running.

Identify any health risks to employees working in your facility and be sure to address these risks in your emergency plan. This will make it much easier to pivot if needed.

Additionally, consider all of the emergencies your practice may face. Do you need to worry about hurricane season? Is your practice at risk from flooding, tornados or other severe weather threats? You also want to ensure you have plans in place for more "mundane" emergencies, such as extended power outages and computer system crashes.

You should also closely review your business interruption insurance policy to make sure it will cover your operating expenses in the case of an unexpected shut down. It is also important to know what events trigger the insurance. Insurance does not always cover everything you'd expect it to, so consider meeting with your insurance broker to better understand what is and is not covered.

By having a plan to address all of these potential emergencies, your practice will be able to more smoothly navigate a crisis.

Beyond an Emergency Plan: What You Can Do Now

A formal emergency plan will take time to develop and communicate to staff. Outside of a formal plan, there are a few other things you can do to help prepare for future emergencies:

- • Take an inventory of PPE and create a system to keep these items well-stocked.
- • Complete a yearly fit test of all employees for N95 masks.
- • Develop enhanced training on infection control precautions.
- • Continue to invest in telemedicine/telehealth.
- Develop patient materials that specify what patients should do when coming in for an appointment or participating in a virtual visit.
- • Revisit your consent process and make updates where needed.
- • Build upon your practice's emergency fund.
- • Re-evaluate your insurance policies to determine exactly what they cover and what they don't.
- • Test your emergency procedures.
- • Cross-train team members to allow for emergency coverage when necessary.

What About Security Breaches and Cyber Attacks?

Consider investing in cyber insurance. There are key categories that are usually standardized in each cyber policy. A comprehensive policy will cover losses resulting from patient data being stolen, exposed or improperly shared. It will also cover breaches from deliberate actions, such as hacking or ransomware, as well as accidents. You'll want to sit down with your insurance broker and compare policies side by side to determine which option is the most cost effective for your practice.

Looking for more practice tips and tools? Head to the practice management section of the AAAAI website.

The AAAAI Annual Meeting Returns as a Hybrid Event in 2022



American Academy of Allergy Asthma & Immunology ANNUAL MEETING PHOENIX, AZ · FEBRUARY 25–28, 2022 Discuss thought-provoking research, practice clinically-relevant skills and connect with colleagues at the 2022 AAAAI Annual Meeting.

The hybrid event will have both in-person and online elements, with the live event taking place February 25-28, 2022, in Phoenix, Arizona. We're excited to be able to offer in-person programming this year. Due to positive member feedback concerning online elements and continuing COVID-19 restrictions, we are also pleased to offer some virtual programming as well.

Watch the <u>Annual Meeting website</u> for more details on next year's event and the hybrid format as the date of the meeting gets closer.





Important Dates September 22 at 11:59 pm CT Case Report Submissions Due

October 6 Registration Opens to Fellows

October 20 Registration Opens to All Members

November 3 Registration Opens to Non-members

The clinical theme of the 2022 AAAAI Annual Meeting is difficult to control asthma.

Plenary Preview

Friday Presidential Plenary: Digital Health and Remote Patient Monitoring for Patients with Difficultto-Control Asthma

Patients with difficult-to-control asthma may have low health literacy, poor inhaled controller medication adherence and technique, high exposure to indoor and outdoor environmental triggers, and reduced access to care. This session will address how digital health technologies and remote patient monitoring systems can address the above challenges, as well as their limitations.

Saturday Plenary: Preparing for the Next Pandemic: From Mechanisms to Vaccines

The worldwide COVID-19 pandemic is the most devastating public health crisis since Spanish influenza in 1918. This session will impart learned strategies to prepare for future pandemics. It will highlight the federal response and how science is leveraged to identify underlying immune mechanisms and rapidly implement novel vaccine strategies.

Sunday Plenary: Anaphylaxis: Novel Mechanisms and Emerging Therapeutic Interventions This session will describe novel discoveries in the field of mast cells, IgE and anaphylaxis. It will also cover novel therapeutic approaches to prevent anaphylaxis.

Monday Plenary: An Ounce of Prevention This session will include presentations from world-renowned experts regarding prevention of food allergy and other allergic diseases. The issue of prevention is of critical importance in the context of increasing prevalence of allergic diseases throughout the world.

Are You an International Fellow-in-Training?

The AAAAI is excited to offer International Fellow-in-Training (FIT) Travel Scholarships to financially assist international FIT members in attending the 2022 AAAAI Annual Meeting.

This grant will reimburse travel, hotel, and meal expenses related to the 2022 Annual Meeting. Rental car, registration fees and abstract fees are not eligible for reimbursement. All applicants must be listed as an author for an abstract accepted for presentation at the Annual Meeting to be eligible. The application for International Travel Scholarships can be completed if an abstract was submitted, even if results are not yet known. The AAAAI will verify abstract acceptance internally when reviewing applications. Applications are due October 4 at 11:59 pm CT and all applicants will be notified of the results in December. You can learn more and apply here.

First Year FITs, Medical Students and Residents: Submit Your Case Reports by September 22

You are invited to submit a case report for the 2022 AAAAI Annual Meeting for the opportunity to share an A/I experience with other Annual Meeting attendees.

Case reports are an excellent way to share new insights about topics in the A/I specialty. The case should include a unique observation and/or a "teachable moment" that would be of value to others in the allergy/immunology community. Submissions are limited to first year FITs who began their A/I training on or after July 1, 2021, as well as medical students or residents. All submissions are due September 22 at 11:59 pm CT. Learn more on the <u>Annual Meeting website</u>.

How You Can Provide the Right Medical Support for Primary Immunodeficiency Patients

Are you interested in reducing the time it takes to diagnose patients with primary immunodeficiency diseases (PIDDs)? Are you curious about available tools and strategies for recognizing, treating and maintaining the optimal health of patients with PIDD? Would you like to implement new knowledge, communication strategies and techniques related to PIDD that align with quality patient care?

If you answered "yes" to any of these questions, then we have an engaging educational course for you to explore.

Providing Enhanced Medical Support for Patients with Primary Immunodeficiency Disorders (PIDD): A Patient-Guided Intervention to Ensure Patient Engagement During a Global Pandemic and Beyond is a new AAAAI course series. To keep the focus on PIDD patients' needs and the provision of optimal care, we went straight to PIDD patients and the literature to find out what to center this education on.

The course begins with a pre-test to determine your experience with PIDD patients. Then, a series of short quizzes will help you determine where to concentrate your efforts in the course.

Symptoms

The symptoms module will help you identify and communicate information about symptoms and medications, as well as collaboratively formulate strategies for next steps toward diagnosis. You will watch a series of video cases that address how to recognize specific PIDD symptoms. You'll also hear from a real patient about their experiences with PIDD management and the importance of effective patient/provider communication. In addition, you can practice identifying PIDD symptoms with a "red flags of immunodeficiency" game.

Beyond the Doctor's Office

This module will focus primarily on telemedicine and how to identify immunology patients who are ideal for a virtual visit. It also covers how to effectively manage an immunology telehealth consultation. A series of short videos and a patient testimonial video will guide you to having a patient-centered consultation. Learn how to create a comfortable rapport with patients online, clearly communicate expectations for a telehealth visit and efficiently address the patient's questions and concerns.

After you complete the course series, you will make note of the ways you can offer enhanced care for PIDD patients in your practice. As a final step, you will be invited to complete a followup self-assessment to share the outcomes you experienced. The American Board of Allergy and Immunology (ABAI) has approved this activity for MOC Part IV Quality Improvement credits.

Get started here.

Diagnosis

The diagnosis module gives you an opportunity to practice what you have learned so far. You will use your skills to develop a systematic approach to patient examination and pursue appropriate diagnostic practices that align with presenting symptoms. Through feedback in the patient cases, you will learn more about how to communicate appropriate and meaningful updates to the patient and confidently respond to their questions regarding next steps.



MPACT

The State of Pollen Data Collection and Research



Benjamin Bolanos Rosero, PhD, the station head of the NAB counting station at the Medical Sciences Campus, University of Puerto Rico - San Juan.

The AAAAI's National Allergy Bureau[™] (NAB[™]) is an incredible resource for the millions of people suffering from allergies to check accurate, local pollen counts. Pollen counting stations do more than just provide pollen and mold counts for the general public, however.

To illustrate this, we asked a few station managers about the types of activities their stations have completed in recent years, including what is being done with data they've collected and their stations' pollen cycle. Here are a few of their responses.

Benjamin Bolanos Rosero, PhD, Medical Sciences Campus, University of Puerto Rico - San Juan, on recent research:

In order to determine the environmental trigger responsible for the high asthma prevalence in Puerto Rico, a collaboration of the NAB San Juan station with the CDC and Puerto Rico Department of Health was established in 2017. We aimed to study the association of outdoor allergens and Saharan/African dust with the asthmarelated health claims in Puerto Rico in 2013 (outpatient and emergency room visits and hospitalizations). We found that the asthma-related utilization of medical services are a reflection of the outdoor levels of tree pollen and fungal spores. Only the fungal spores and Saharan dust were significant triggers of asthma in Puerto Rico. These findings will allow us to establish better preventive measures to keep asthma under control. The result of this collaboration was published in the *Journal of Asthma* in 2019. We've also developed the TOTAAL App that carries the pollen and mold levels for the San Juan station with over 6,000 downloads. In addition, we are present on social media with the "Alergia a hongos" Facebook page that has over 29,000 followers.

Jonathan Matz, MD, FAAAAI, Owing Mills, Maryland station, on the local pollen cycle and research:

Tree Pollen: Starts in late February, peaks the last week of April and ends mid-June.

Grass Pollen: Starts at the end of April/ early May, peaks during the last week of May, with low levels through the summer and another minor peak in September.



Ragweed: Starts August 20, peaks September 7-9 and ends by early October.

I have participated in multiple clinical studies on asthma and allergies, and recently been requested to participate in federally sponsored research with the University of Maryland on the allergenic pollen impact on asthma emergency room visits and hospital admissions.

Susan E. Kosisky, BS, MHA, U.S. Army Centralized Allergen Extract Lab, on the importance of the NAB:

The U.S. Army Centralized Allergen Extract Laboratory (USACAEL) in Silver Spring, Maryland has contributed our pollen counts to the NAB for many years. The NAB continues to be an invaluable resource for the collection



and presentation of data utilized by scientific and public health communities worldwide. Over the years, the NAB has created a forum for which the expertise and work efforts of aerobiologists can be shared and utilized for purposeful scientific investigations. Increasing the public's knowledge of major area aeroallergens and their periodicity has helped to facilitate the practice of more effective avoidance measures for the sensitized patient.

You can help to contribute to data like this by <u>becoming a counter</u> or starting a <u>NAB Pollen/Mold Counting Station</u>.

IN BRIEF

Have You Just Finished Your Fellowship Training?

If you recently graduated from your A/I training program, your AAAAI fellow-in-training (FIT) membership automatically transitions to full membership. In addition, you will be added as a member of the New Allergist/Immunologist Assembly (NAIA). NAIA is made up of hundreds of allergist/immunologists within the first five years of completing their A/I training. We encourage you to get involved with NAIA to grow your professional network and identify what areas of the field you most want to make contributions to during your career.

Make sure to sign up for the <u>NAIA Listserv</u> to chat with other AAAAI members early in their careers. You may also be interested in participating in the NAIA-FIT mentor/mentee program, or serving as a presenter for the <u>Virtual Journal Club</u>. If you have any questions about NAIA, email <u>arjohnson@aaaai.org</u>.

JACI: *In Practice* Announces New Case Studies in Health Disparities Feature

Case Studies in Health Disparities is a new series will soon appear in issues of JACI: *In Practice*. The aim is to feature case reports with particular attention given to highlighting any social determinants of health that are relevant to the case. Salient features of the case should be integrated into the discussion and the specific social determinants of health relevant to allergy/immunology clinical care should be clarified. These case studies will also provide practical actionable steps that a clinician can apply with similar future patients.

For more information about this new feature, email InPractice@aaaai.org.

Teaching Slides Now Easier to Access

With the launch of the new website, we've moved the teaching slides to make them easier to access. You will find them at aaaai.org under the <u>"Professional Education" dropdown menu</u>. You'll still need to log in to download the slides, but they're now much easier to find and access. These teaching slides cover a variety of topics and can be downloaded and used in your own presentations.

Read AAAAI Journal Summaries on the AAAAI Website

Did you know that you can find summaries of recent journal articles on the AAAAI website? These summaries are a great way to stay updated on recent research if you haven't had time to read the AAAAI's journals. You can find research summaries from JACI and JACI: *In Practice* <u>here</u>.

2021 Virtual Practice Management Recordings Now Available

We are pleased to announce that all of our educational sessions from the 2021 AAAAI Virtual Practice Management Workshop are available online now as recordings. Learn more about the practice topics you care about on your own time by purchasing the recordings package, which includes plenaries and the presentations from interactive sessions offered during the live event. You can purchase the <u>recordings package here</u>.

Help Us Spread Awareness About Penicillin Allergy Testing

September 28 is National Penicillin Allergy Day. The AAAAI is working hard to inform the public and other healthcare professionals about how unverified penicillin allergies contributes to antibiotic resistance. Click <u>here</u> to find our resources, and keep an eye out for updated tools that will help us spread the word.



June 2021 Board of Directors Meeting Summary

The members of the AAAAI Board of Directors met both virtually and in person June 4-6, 2021, in Chicago, Illinois, to discuss current and future activities.

The members of the Board of Directors appreciate the work of AAAAI committee members and chairs as they strive toward the AAAAI mission to advance the knowledge and practice of allergy, asthma and immunology for optimal patient care. Over the course of the meeting, a number of significant decisions and actions were made. Here are the highlights:



The majority of the <u>2021-2022 AAAAI Board of Directors</u>, as well as Executive Vice President Thomas A. Fleisher, MD, FAAAAI, are pictured here as they gathered in Chicago for the first in-person Board meeting since November 2019. Not pictured are Board members Paula J. Busse, MD, FAAAAI, Timothy J. Craig, DO, FAAAAI, Denise A. DiPrimio-Kalman, DO, FAAAAI, and Wanda Phipatanakul, MD, MS, FAAAAI, who joined virtually.

Approvals

A number of requests were granted approval, including funding for a 2022 AAAAI Leadership Summit and to update the Online Disclosure System. The eligibility criteria amendments for Medical Student and Resident Travel Scholarships was approved, which allows those without an accepted abstract or case report to receive financial support. Amendments to the governance structure of the AAAAI Foundation Council were also approved. Additionally on the AAAAI Foundation side, approval was granted to present up to four Faculty Development Awards in 2022. The 2022 AAAAI Honorary Award recipients were also approved.

Presidential Presentations

AAAAI President Giselle S. Mosnaim, MD, MS, FAAAAI, provided further insights on her presidential initiatives, including her three presidential task forces. These task forces include the Community Practitioner Leadership Task Force, Culture of Leadership Task Force, and Disparities Task Force. Incoming AAAAI President David A. Khan, MD, FAAAAI, provided a first look at his presidential initiatives for 2022.

Miscellaneous

A number of other projects and topics were discussed, including potential funding for a Leadership Institute project to survey medical students on their interest in allergy/immunology. The Editor-in-Chief for the new AAAAI Gold Open Access journal, which will be titled JACI: *Global*, was selected as David B. Peden, MD, MS, FAAAAI. Discussions about the possible division of the RSLAAIS Region 6 territory into two separate regions was discussed as well. Award funding was also discussed regarding the 2022 AAAAI/Hope APFED Grant and the AAAAI Educator Development Award for 2022.

What The next Board of Directors meeting When November 12-14, 2021 Where Washington, DC

AAAAI Welcomes Incoming Fellows and Members

The following individuals were recently approved by the AAAAI Board of Directors. Eligible voting members have 30 days to comment, in writing, regarding the proposed slate as a whole or a specific proposed member. You may send comments to membership@aaaai.org.

Fellow to Emeritus Fellow

Susan Bromberg Schneider, MD, FAAAAI Ellen Maud Buchbinder, MD, FAAAAI Bruce F. Corsello, MD, FAAAAI Seshagiri R. Dandamudi, MD, FAAAAI M. Eric Gershwin, MD, FAAAAI Thomas B. Harper, III, MD, FAAAAI Claus K. Helbing, MD, PhD, FAAAAI J. Allen Thiel, MD, FAAAAI Anat Binstein Warren, MD, FAAAAI Steven C. Whited, MD, FAAAAI

Member to Emeritus Member

Gene L. France, MD Patricia Mary Nolan, MD Nicholas A. Pawlowski, MD Kamlesh S. Shah, MD Pradeep Sharma, MD

Fellow

John T. Anderson, MD Sarah M. Boudreau-Romano, MD Kathleen M. Buchheit, MD Adeeb A. Bulkhi, MD Katherine N. Cahill, MD Jinny E. Chang, MD R. Sharon Chinthrajah, MD Charles W. DeBrosse, MD Scott A. Dyer, DO Katharine Fast, MD Matthew Feldman, MD Laura M. Gober, MD Sarah E. Henrickson, MD, PhD Alice E.W. Hoyt, MD Pooja Jhaveri, MD Mark H. Kaplan, PhD Barzin Khalili, MD Bharat Kumar, MD Merin Elizabeth Kuruvilla, MD Christina G. Kwong, MD Sebastian S. Lighvani, MD Brooke I. Polk, MD Minto K. Porter, MD Cristine Radojicic, MD Andrew C. Rorie, MD Kelvin S. Shaw, MD Jennifer Toh, MD

International Fellow

Akio Mori, MD, PhD

Member

Paul M. Guyre, PhD Brian WP Seymour, PhD, BS, MS

International Member

Perla R. Alcaraz Duarte, MD Joana Vitte, MD, PhD

Allied Health Member

Kari D. Coats, CPNP Margaret M. Curry, RN Christine Dale, FNP-BC Sary De La Rosa, MSN Brandi Hill, NP Heather M. Hill Esther P. Lange, CRNP Darlene M. Madore, NP Tamichole M. Nelson, RN Shauna Rafferty, FNP Amanda S. Ramirez, RMA Thanomkwan Sathissarat Brianna L. Sayre, APRN Nicole M. Soucy, PA-C Benjamin Willett, PA

In-Training Member

Faisal A. ALMuhizi Nora Alrumayyan, MD Yatyng Chang, MD Nicole Christians, MD Daniel J. Groth, MD Mariam Majzoub, MD Mark McCabe Charles K. Miller, MD Misu Paul, MD David A. Sanchez, MD Nicholas Scanlon, MD Shamsa Shafi, MD Elsa Treffeisen, MD

International In-Training Member

Sarah M. Albesher, II, MD Fernando Aleman Paramo, MD Maryam Alkhaja, MD Chortip Chansangsawat, MD Patcharat Chiamruchikun Laís L. G. Cunha, MD Tania Delgado, MD Grecia Jaqueline Hernandez Salcido, MD Daniela P. Navarrete-Cortes, Sr., MD Tess E. O'Gorman Andrea Otero Alonso Daniela Robles Rodríguez, MD Pornsiri Sae-lim Pattiya Srisakdi, MD Claire ML Teo, MBBS, MRCP, MMed Jesus Eduardo Uc Rosado, MD Jirakiti Wongnate

PhD/Post Doctoral Member

Mohammad Asad, PhD Juan C. Garcia-Saucedo Miwa Shinohara, MD, PhD Anand Sripada

International PhD/ Post Doctoral Member

Samantha Chan Mahnaz Jamee, MD Nikolaos Tzenios



New Fellows and Members

Resident

Sarah Y. Afzal, MD Adnan M. Al Ali, MBBS Nathalia Albarracin, MD Jordan Arends, DO Russell G. Behmer, MD Taya Carpenter, MD Andria Cheramie, DO, MPH Krishan Chhiba, MD Michael J. Dohar, III, MD Eilaf I. Fallatah, MD Sonia Gandhi, MD Yasamin N. Ghiasi, MD Ana Luiza O. Graneiro, MD Christopher S. Greb, MD Carly A. Gunderson, MD Emily Haltigan, MD Jacquelyn Hunter, MD

Eric M. Jorgensen, MD Yela Jung, MD Hajra M. Khan, MD Antonio Petralia, MD Michael A. Phillips, MD Emily E. Potter, DO Cynthia Pung, MD Danielle M. Rodgers, MD Devyn L. Rohlfs, MD Armen Sanosyan, MD Maria A. Strobel, MD Priyal Upadhyay, MD Vincent T. Vertalino, MD Frederico Villa-Chan, MD Jason Wong, MD Ashley Y. Wu, MD Jose L. Zamora-Sifuentes, DO Elena Zidan, MD

Doctoral Graduate/ Medical Student

Eisha Ahmed Jamie Y. Choe Adnan Divjan Jacob H. Elnaggar Dovid Kotkes Amy Lin Shannon Manz Sophia McGregor Michael Nordness Derek Nye Ahraz Rizvi Rayna Schwartz Hunter G. Smith, MPH Priya Vedula **Benjamin** Watt Reena Yaman

PRIME



Evidence-based Actions for Inclusive Practices

REGISTER NOW: LIVECME.ORG/ASTHMACARE

WEDNESDAY, OCT 27, 2021 2:00 PM EASTERN

free 1.0 CME/CE

AAAAI FOUNDATION 🔬 📝 🔊 🔬 🧬

FOUNDATION

Funding research that leads to th prevention and cure of asthma an allergic and immunologic diseas

2022 AWARD TIMELINE

Letter of Intent Opens: Letter of Intent Due: Top Finalists Notified: Complete Applications Due: Review Results Announced: July 6, 2021 September 7, 2021 October 11, 2021 November 12, 2021 January 2022

This mentored award provides \$240,000 in funding over a three-year period and is intended to support the development of careers in Allergy and Immunology. Multiple awards will be made to further the development of junior faculty into independent investigators by funding excellent research that leads to the prevention and cure of asthma and allergic and immunologic diseases.

The AAAAI Foundation is committed to increasing ethnic and racial diversity in the A/I field, and strongly encourages minority applicants to apply. Further, the AAAAI Foundation is committed to geographic diversity in the A/I field, and strongly encourages applications from diverse geographic areas.

Eligibility:

- Must be board certified in A/I by the American Board of Allergy and Immunology (ABAI) or hold the equivalent certification from the Royal College of Physicians and Surgeons of Canada (RCPSC).
- At the time of Letter of Intent, applicant must be no more than 5 years post the ACGME mandated training program requirement of 2 years in A/I.
- Primary faculty appointment must be in the discipline of A/I and the applicant needs to have a current mentor.
- One of the following degrees: MD, MD/PhD, DO, DO/PhD.
- Applicants must be citizens or permanent residents of the United States or Canada.
- Applicants must be AAAAI members or submit a membership application prior to submitting a Letter of Intent.
- No program can have more than 2 active Foundation Faculty Development Awards.
- A sponsoring university or institution that has multiple A/I training programs cannot have more than three active awards.

Award term is July 1, 2022 to June 30, 2025.

For complete details, please visit **aaaaifoundation.org/research**



American Academy of Allergy, Asthma & Immunology Foundation 555 East Wells Street, Suite 1100 • Milwaukee, WI 53202 • 414-272-6071 • aaaai.org

Apply today for the opportunity to have your research supported for three years!